What happened with GKOS today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Glaukos Corporation sells products that eye surgeons use to treat glaucoma and corneal disorders. Most sales come from the iStent family of minimally invasive glaucoma surgery devices, iDose TR implants that deliver medicine inside the eye over extended periods, and related glaucoma accessories. Surgery centers, hospitals and private physician practices buy its products, mostly through its own sales teams in the United States.
Its smaller corneal-health business sells iLink therapies and associated systems for keratoconus. These treatments use medicine activated by ultraviolet light to strengthen and stabilize the cornea.
Most revenue comes from U.S. customers, without a dominant single customer or distributor. Demand depends on physicians adopting the treatments and on government and private insurers covering the products and procedures at adequate payment levels. Marketing must stay within approved labeling. To obtain coverage for certain drugs under federal healthcare programs, Glaukos must pay Medicaid rebates and sell covered outpatient drugs to eligible healthcare organizations under the 340B program’s price ceilings, limiting what it can collect on those sales.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Glaukos's results depend chiefly on glaucoma-treatment adoption and reimbursement; privately held New World Medical is also an important surgical rival to watch outside this list.
Sight Sciences competes for the same surgical facilities and ophthalmologists buying Glaukos's iStent and iDose TR, selling them OMNI and SION devices for glaucoma procedures. Watch OMNI usage: Sight Sciences says doctors' adoption of alternative products has hurt its utilization and revenue growth.
Alcon competes with Glaukos for ophthalmic surgeons' choices in minimally invasive glaucoma surgery, while selling a broader range of implants, surgical supplies and equipment. Its surgical business is the relevant area to watch, rather than its contact-lens and ocular-health sales.
AbbVie's glaucoma surgical offerings and long-acting drug treatments compete with Glaukos's iStent devices and iDose TR for glaucoma treatment. Watch progress on AbbVie's implant that releases medicine inside the eye over time, rather than its company-wide medicine sales.
SpyGlass Pharma is developing a long-acting glaucoma drug-delivery system that would challenge Glaukos's iDose TR, but had no product-sales revenue through December 31, 2025. Watch its BIM-IOL clinical progress and the pending trade-secret lawsuit: a court barred SpyGlass from using materials Glaukos alleges were taken by a former employee, with trial set for October 27, 2026.
Iridex sells ophthalmologists glaucoma laser systems as an alternative to Glaukos's implants and surgical devices. Watch its Cyclo G6 glaucoma system rather than overall laser sales, which also include retinal treatments; Iridex does not disclose revenue by product line.
Ocular Therapeutix is developing therapies that release medicine in the eye over time, competing with Glaukos's glaucoma and retinal drug-delivery programs. Its AXPAXLI and OTX-TIC development progress is more relevant to that rivalry than sales of DEXTENZA, its approved treatment for specified eye inflammation, pain and itching indications.
Bausch + Lomb sells glaucoma medicines including Vyzulta, giving glaucoma patients an alternative to Glaukos's treatments for lowering eye pressure.
Glaukos Corporation earningsThis company
Glaukos's report will show whether iDose TR-led glaucoma growth can also stabilize sales of its other products and improve gross margin.
Read iDose TR sales, sales of other glaucoma products, and gross margin together. If iDose TR grows, other products hold steady, and gross margin improves, growth is spreading beyond one higher-priced product and translating into better sales mix and manufacturing economics. If other products keep falling or margin remains under pressure, growth is still concentrated in iDose TR, while costs or product mix continue to weigh on profitability.
Bausch + Lomb Corporation earningsBLCO
Bausch + Lomb's report will show whether its glaucoma medicines are drawing patients and prescribers as an alternative to Glaukos's treatments for lowering eye pressure.
Look for Bausch + Lomb's reported glaucoma-medicine sales or demand clues, not its company-wide results. Stronger demand would show that lowering eye pressure with medicines remains an appealing route, making the alternative to Glaukos's devices and drug-delivery implant more substantial. Weaker demand would offer less evidence of that competitive pull, but would not prove demand for Glaukos products is rising.
Sight Sciences, Inc. earningsSGHT
Sight Sciences's report will show how use of its OMNI and SION glaucoma devices is changing, offering a read on its competition with Glaukos for the same surgeons and facilities.
Watch whether OMNI utilization and related revenue move together, and what Sight Sciences says about doctors adopting alternatives. Rising use and revenue would show this rival is gaining strength among the same ophthalmologists and surgical facilities, potentially intensifying competition for Glaukos's iStent and iDose TR. Continued declines would point to less pressure from Sight Sciences, but would not mean Glaukos necessarily wins those procedures.
